

Special Issue

Vaccine-Induced Humoral Immunity: Mechanisms of Induction and Idiotypic Network Interactions

Message from the Guest Editor

This Special Issue aims to gather original research and comprehensive reviews that deepen our understanding of vaccine-induced humoral immunity across all antibody isotypes. We invite contributions exploring the mechanisms that drive effective antibody responses elicited by both conventional and next-generation vaccine platforms. We place particular emphasis on studies examining idiotypic and anti-idiotypic interactions shaped by vaccination, as well as their potential roles in immune regulation, vaccine efficacy, and safety. Submissions based on in vitro experiments, animal models, human studies, and systematic reviews are welcome. Please note that case reports will not be considered. We especially encourage innovative, cross-disciplinary approaches that offer novel perspectives or challenge existing paradigms, with the goal of fostering a dynamic and forward-looking discussion on the complexity of vaccine-induced humoral immunity. I look forward to your valuable contributions.

Guest Editor

Dr. Jefferson Russo Victor
Department of Dermatology, University of São Paulo, São Paulo, Brazil

Deadline for manuscript submissions

30 June 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/240473

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).